The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $168.97 in the prior trading day, Charles River Laboratories International Inc (NYSE: CRL) closed at $173.5, up 2.68%. In other words, the price has increased by $2.68 from its previous closing price. On the day, 0.92 million shares were traded. CRL stock price reached its highest trading level at $175.55 during the session, while it also had its lowest trading level at $167.6.
Ratios:
Our goal is to gain a better understanding of CRL by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 41.12 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.71. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.37. In the meantime, Its Debt-to-Equity ratio is 0.77 whereas as Long-Term Debt/Eq ratio is at 0.77.
Barclays Upgraded its Equal Weight to Overweight on October 02, 2025, while the target price for the stock was maintained at $195.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 22 ’25 when Joseph LaPlume bought 400 shares for $152.50 per share.
LaPlume Joseph W sold 800 shares of CRL for $126,080 on Aug 18 ’25. The EVP, Corp Strategy & Develop now owns 24,116 shares after completing the transaction at $157.60 per share. On Aug 18 ’25, another insider, WALLMAN RICHARD F, who serves as the Former Director of the company, bought 22,500 shares for $152.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRL now has a Market Capitalization of 8538884608 and an Enterprise Value of 11008429056. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.12 while its Price-to-Book (P/B) ratio in mrq is 2.51. Its current Enterprise Value per Revenue stands at 2.736 whereas that against EBITDA is 12.422.
Stock Price History:
The Beta on a monthly basis for CRL is 1.64, which has changed by -0.18190181 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, CRL has reached a high of $222.10, while it has fallen to a 52-week low of $91.86. The 50-Day Moving Average of the stock is 3.08%, while the 200-Day Moving Average is calculated to be 11.99%.
Shares Statistics:
The stock has traded on average 992.07K shares per day over the past 3-months and 1307070 shares per day over the last 10 days, according to various share statistics. A total of 49.22M shares are outstanding, with a floating share count of 48.66M. Insiders hold about 1.12% of the company’s shares, while institutions hold 103.90% stake in the company. Shares short for CRL as of 1761868800 were 2434747 with a Short Ratio of 2.10, compared to 1759190400 on 2207028. Therefore, it implies a Short% of Shares Outstanding of 2434747 and a Short% of Float of 5.6900002.
Earnings Estimates
A comprehensive evaluation of Charles River Laboratories International Inc (CRL) is underway, with the input of 14.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $2.56, with high estimates of $2.78 and low estimates of $2.37.
Analysts are recommending an EPS of between $10.34 and $10.1 for the fiscal current year, implying an average EPS of $10.23. EPS for the following year is $10.95, with 16.0 analysts recommending between $12.36 and $10.35.
Revenue Estimates
11 analysts predict $985.17M in revenue for. The current quarter. It ranges from a high estimate of $1B to a low estimate of $974.7M. As of. The current estimate, Charles River Laboratories International Inc’s year-ago sales were $1BFor the next quarter, 11 analysts are estimating revenue of $998.69M. There is a high estimate of $1.03B for the next quarter, whereas the lowest estimate is $981.93M.
A total of 15 analysts have provided revenue estimates for CRL’s current fiscal year. The highest revenue estimate was $4.03B, while the lowest revenue estimate was $3.94B, resulting in an average revenue estimate of $4B. In the same quarter a year ago, actual revenue was $4.05BBased on 15 analysts’ estimates, the company’s revenue will be $4.08B in the next fiscal year. The high estimate is $4.16B and the low estimate is $4.03B.
